This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignees: Helmholtz-Zentrum Dresden-Rossendorf - Institute of Radiopharmaceutical Cancer Research, Instituto Portugues De Oncologia Do Porto Fg, Epe, Universidade Nova De Lisboa. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 7 Years Active: 2022
Title: Lúcio Lara Santos: Pioneering Antibody Innovations in Cancer Research
Introduction
Lúcio Lara Santos, an innovative inventor based in Caparica, Portugal, has made significant strides in the field of cancer research through his contributions to monoclonal antibody technology. With one patent to his name, Santos has showcased his commitment to finding new ways to combat tumour antigens and improve patient outcomes.
Latest Patents
Santos holds a patent for the L2A5 antibody or functional fragment thereof against tumour antigens. This groundbreaking invention presents an antibody or its functional fragments directed against a unique group of antigens identified in cancer. The patent reveals that the invention comprises nucleotide sequences derived from the L2A5 monoclonal antibody. The unique DNA/amino acid sequence conjugation described in this patent is innovative and has not been previously documented. This invention is not only crucial for the detection of cancer but also holds promise for treatment and prevention, marking a significant advancement in medical biotechnology.
Career Highlights
Throughout his career, Lúcio Lara Santos has worked with prestigious institutions that have furthered his research. He has been associated with Universidade Nova de Lisboa and the Instituto Português De Oncologia Do Porto, Fg, Epe. His tenure at these institutions has allowed him to engage in advanced research and development in the area of oncology, leading to the creation of impactful therapeutic solutions.
Collaborations
Santos has collaborated with notable peers, including Paula Alexandra Quintela Videira and Carlos Manuel Mendes Novo. These collaborations have likely enhanced the research environment and led to the exchange of innovative ideas, contributing to the advancement of cancer treatment methodologies.
Conclusion
Lúcio Lara Santos continues to be a driving force in antibody innovation, particularly in the realm of cancer research. His patent for the L2A5 antibody signifies not just an academic achievement but a beacon of hope for improved diagnostics and treatments for human diseases. His work exemplifies the critical role of inventors in advancing healthcare and technology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile